Phase 1 Safety and Pharmacokinetics of Methane Sulfonylfluoride (MSF or SNX-001) After Single and Multiple Oral Dose Administration in Healthy Adult Aged Volunteers

Trial Profile

Phase 1 Safety and Pharmacokinetics of Methane Sulfonylfluoride (MSF or SNX-001) After Single and Multiple Oral Dose Administration in Healthy Adult Aged Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Sep 2015

At a glance

  • Drugs Methanesulfonyl fluoride (Primary)
  • Indications Alzheimer's disease; Cognition disorders
  • Focus Adverse reactions
  • Sponsors SeneXta Therapeutics
  • Most Recent Events

    • 01 Nov 2012 Results published in the British Journal of Clinical Pharmacology.
    • 06 Jan 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top